

## Ezetimibe / Atorvastatin Formulation

Version 9.0      Revision Date: 2024/04/06      SDS Number: 26493-00022      Date of last issue: 2023/09/29  
Date of first issue: 2014/10/29

---

**1. PRODUCT AND COMPANY IDENTIFICATION**

Chemical product name : Ezetimibe / Atorvastatin Formulation

**Supplier's company name, address and phone number**

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

E-mail address : EHSSTEWARD@organon.com

Emergency telephone number : +1-215-631-6999

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

**2. HAZARDS IDENTIFICATION****GHS classification of chemical product**

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Liver, muscle)

Long-term (chronic) aquatic hazard : Category 2

**GHS label elements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
**Response:**

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

P314 Get medical advice/ attention if you feel unwell.  
P391 Collect spillage.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Important symptoms and out- : Dust contact with the eyes can lead to mechanical irritation.  
lines of the emergency as- : Contact with dust can cause mechanical irritation or drying of  
sumed : the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	$\geq 20 - < 30$	
Atorvastatin	134523-03-8	$\geq 10 - < 20$	
Ezetimibe	163222-33-1	$\geq 2.5 - < 10$	
Magnesium stearate	557-04-0	$> 0 - < 10$	2-611
Sodium n-dodecyl sulfate	151-21-3	$\geq 0.25 - < 1$	2-1679

**4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.  
Contact with dust can cause mechanical irritation or drying of the skin.

Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.  
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

Notes to physician : when the potential for exposure exists (see section 8).  
: Treat symptomatically and supportively.

---

**5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

## Ezetimibe / Atorvastatin Formulation

Version 9.0	Revision Date: 2024/04/06	SDS Number: 26493-00022	Date of last issue: 2023/09/29 Date of first issue: 2014/10/29
----------------	------------------------------	----------------------------	---

mine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**7. HANDLING AND STORAGE**
**Handling**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Storage**

- Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

---

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type	Control parame-	Basis
------------	---------	------------	-----------------	-------

# SAFETY DATA SHEET



## Ezetimibe / Atorvastatin Formulation



Version 9.0      Revision Date: 2024/04/06      SDS Number: 26493-00022      Date of last issue: 2023/09/29  
Date of first issue: 2014/10/29

		(Form of exposure)	ters / Reference concentration / Permissible concentration	
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Atorvastatin	134523-03-8	TWA	0.05 mg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	0.5 mg/100 cm <sup>2</sup>	Internal
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

# SAFETY DATA SHEET



## Ezetimibe / Atorvastatin Formulation



Version 9.0      Revision Date: 2024/04/06      SDS Number: 26493-00022      Date of last issue: 2023/09/29  
Date of first issue: 2014/10/29

---

Physical state : powder

Colour : off-white

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit  
Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Decomposition temperature : No data available

pH : No data available

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : 0.01 g/l

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Density and / or relative density  
Relative density : No data available

Density : No data available

Relative vapour density : No data available

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

---

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

**Atorvastatin:**

Acute oral toxicity	:	LD50 (Rat, male and female): > 5,000 mg/kg LD50 (Mouse, male and female): > 5,000 mg/kg
---------------------	---	--

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

||

**Ezetimibe:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
		LD50 (Mouse): > 5,000 mg/kg
		LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intraperitoneal
		LD50 (Mouse): > 1,000 - < 2,000 mg/kg Application Route: Intraperitoneal

**Magnesium stearate:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		Method: OECD Test Guideline 423
		Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Acute oral toxicity	:	LD50 (Rat): 1,200 mg/kg
		Method: OECD Test Guideline 401
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg
		Method: OECD Test Guideline 402
		Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Atorvastatin:**

Species	:	Rabbit
Result	:	No skin irritation

**Ezetimibe:**

Species	:	Rabbit
Result	:	No skin irritation



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

**Magnesium stearate:**

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Species	: Rabbit
Result	: Skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Atorvastatin:**

Species	: Rabbit
Result	: No eye irritation
Method	: Draize Test

**Ezetimibe:**

Species	: Rabbit
Result	: No eye irritation

**Magnesium stearate:**

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Species	: Rabbit
Result	: Irreversible effects on the eye
Method	: OECD Test Guideline 405

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Atorvastatin:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

**Ezetimibe:**

Test Type	: Maximisation Test
Species	: Guinea pig
Result	: negative

**Magnesium stearate:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative
Remarks	: Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
Genotoxicity in vivo	: Test Type: In vitro mammalian cell gene mutation test
	Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
	Species: Mouse
	Application Route: Ingestion
	Result: negative

**Atorvastatin:**

Genotoxicity in vitro	: Test Type: reverse mutation assay
	Test system: Salmonella typhimurium
	Result: negative
Genotoxicity in vitro	: Test Type: reverse mutation assay
	Test system: Escherichia coli
	Result: negative
Genotoxicity in vivo	: Test Type: In vitro mammalian cell gene mutation test
	Test system: Chinese hamster lung cells
	Result: negative

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

Genotoxicity in vivo : Test Type: sister chromatid exchange assay  
Test system: Chinese hamster lung cells  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Ezetimibe:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Metabolic activation: with and without metabolic activation  
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)  
Species: Mouse

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Atorvastatin:**

Species : Mouse, male and female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
LOAEL : 400 mg/kg body weight  
Result : negative  
Target Organs : Liver

Species : Rat, female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
LOAEL : 100 mg/kg body weight  
Target Organs : Musculo-skeletal system

**Ezetimibe:**

Species : Rat, female  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Rat, male  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Mouse  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

**Sodium n-dodecyl sulfate:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Method : OECD Test Guideline 453

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

Result	: negative
Remarks	: Based on data from similar materials

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

**Atorvastatin:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, female Fertility: NOAEL: 225 mg/kg body weight Result: No effects on fertility
	Test Type: Fertility/early embryonic development Species: Rat, male Fertility: NOAEL: 175 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Species: Rat, female Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: No teratogenic effects, Embryo-foetal toxicity Remarks: Maternal toxicity observed.
	Species: Rabbit, female Application Route: Oral Developmental Toxicity: NOAEL: 100 mg/kg body weight Result: No embryo-foetal toxicity

**Ezetimibe:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male and female Fertility: NOAEL: > 1,000 mg/kg body weight Result: No effects on fertility, No fetotoxicity
Effects on foetal development	: Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight Result: No adverse effects

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
 Result: No adverse effects

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 416  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

**Components:****Atorvastatin:**

Exposure routes : Ingestion  
 Target Organs : Liver, muscle  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

## Ezetimibe / Atorvastatin Formulation

Version 9.0      Revision Date: 2024/04/06      SDS Number: 26493-00022      Date of last issue: 2023/09/29  
Date of first issue: 2014/10/29

---

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Atorvastatin:**

Species : Rat, male and female  
LOAEL : 70 mg/kg  
Application Route : oral (gavage)  
Exposure time : 52 Weeks  
Target Organs : Liver

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : oral (gavage)  
Exposure time : 104 Weeks  
Target Organs : Liver

**Ezetimibe:**

Species : Dog  
NOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 1,500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Remarks : No significant adverse effects were reported

**Magnesium stearate:**

Species : Rat

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Species	:	Rat
NOAEL	:	488 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Components:****Ezetimibe:**

Not applicable

**Experience with human exposure****Components:****Atorvastatin:**

Ingestion	:	Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change
-----------	---	---

**Ezetimibe:**

Ingestion	:	Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain
-----------	---	--

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

**Atorvastatin:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
------------------	---	--



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 200 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.49 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.2 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition

**Ezetimibe:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 4 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility  NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l Exposure time: 33 d

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

		Method: OECD Test Guideline 210
		NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.282 mg/l Exposure time: 21 d Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: > 4.4 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
		NOEC: 4.4 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

**Magnesium stearate:**

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility
		NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l  
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l  
 Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l  
 Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l  
 Exposure time: 72 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): >= 1.357 mg/l  
 Exposure time: 42 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 0.88 mg/l  
 Exposure time: 7 d

Toxicity to microorganisms : EC50: 135 mg/l  
 Exposure time: 3 h

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Atorvastatin:**

Biodegradability : Result: Not readily biodegradable.  
 Biodegradation: 7.7 %  
 Exposure time: 28 d  
 Method: OECD Test Guideline 314

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
 Biodegradation: 6.8 %  
 Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
 Method: OECD Test Guideline 111

## Ezetimibe / Atorvastatin Formulation

Version 9.0      Revision Date: 2024/04/06      SDS Number: 26493-00022      Date of last issue: 2023/09/29  
Date of first issue: 2014/10/29

---

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Sodium n-dodecyl sulfate:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 95 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

**Bioaccumulative potential****Components:****Atorvastatin:**

Partition coefficient: n-octanol/water : log Pow: 1.62

**Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Sodium n-dodecyl sulfate:**

Partition coefficient: n-octanol/water : log Pow: 0.83

**Mobility in soil****Components:****Atorvastatin:**

Distribution among environmental compartments : log Koc: 2.84

**Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

---

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Atorvastatin)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Ezetimibe, Atorvastatin)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Atorvastatin)

Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**ERG Code** : 171

**15. REGULATORY INFORMATION****Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Chemical Substance Control Law**

Priority Assessment Chemical Substance

Chemical name	Number
Sodium alkyl(C=8-18) sulfate	214

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Substances Subject to be Notified Names**

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>0 - <10	-

**Substances Subject to be Indicated Names**

Article 57 (Enforcement Order Article 18)

Chemical name	Remarks
Magnesium stearate	-

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

### **Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

### **Ordinance on Prevention of Lead Poisoning**

Not applicable

### **Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

### **Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

### **Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

### **Poisonous and Deleterious Substances Control Law**

Not applicable

### **Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

### **High Pressure Gas Safety Act**

Not applicable

### **Explosive Control Law**

Not applicable

### **Vessel Safety Law**

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

### **Aviation Law**

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

### **Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Classified as marine pollutant

### **Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

### **Waste Disposal and Public Cleansing Law**

Industrial waste

### **The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

IECSC : not determined

---

**16. OTHER INFORMATION**

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-



# SAFETY DATA SHEET



## Ezetimibe / Atorvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/29
9.0	2024/04/06	26493-00022	Date of first issue: 2014/10/29

---

recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN